Shibani Nicum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shibani Nicum has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Bhupinder Sharma
Department of Imaging, Royal Marsden Hospital, London, UK
1 shared publication - James S Myerson
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
1 shared publication - Mary E.R. O'BRien
The Royal Marsden NHS Foundation Trust, Sutton, UK Mary.O'
1 shared publication Mary Er O’bRien
1 shared publication
Latest Publications
- Open Access
- 28 April 2008
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 2 (1) , 125
Malignant mesothelioma with unexpected contralateral mediastinal shift: a case report
Contralateral mediastinal shift due to pleural mesothelioma tissue, rather than a pleural effusion, is an unusual clinical feature of mesothelioma.
- 28 April 2008
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 2 (1) , 125
Open AccessMalignant mesothelioma with unexpected contralateral mediastinal shift: a case report
Contralateral mediastinal shift due to pleural mesothelioma tissue, rather than a pleural effusion, is an unusual clinical feature of mesothelioma.
- 1 June 2007
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 7 (6) , 795-801
Topotecan for the treatment of small-cell lung cancer
Lung cancer is the most prevalent and yet the most preventable malignancy worldwide. Owing to the propensity of small-cell lung cancer to early relapse and its relative resistance to subsequent treatment there is a need to improve currently available therapies. Topotecan has provided an efficacious and tolerable therapeutic option for patients with recurrent small-cell lung cancer, and the oral formulation has also been shown to be beneficial, even in elderly patients of poor performance status. Herein we review the role of topotecan in the treatment of small-cell lung cancer.
- 1 June 2007
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 7 (6) , 795-801
Topotecan for the treatment of small-cell lung cancer
Lung cancer is the most prevalent and yet the most preventable malignancy worldwide. Owing to the propensity of small-cell lung cancer to early relapse and its relative resistance to subsequent treatment there is a need to improve currently available therapies. Topotecan has provided an efficacious and tolerable therapeutic option for patients with recurrent small-cell lung cancer, and the oral formulation has also been shown to be beneficial, even in elderly patients of poor performance status. Herein we review the role of topotecan in the treatment of small-cell lung cancer.